



WCIRDC 2025 (World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease)

December 3-6, 2025; Los Angeles, CA; Resource Hub – Draft

---

**Welcome to our resource hub for WCIRDC 2025!** This is a one-stop-shop for all your WCIRDC 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

## Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Top Highlights](#)

[Previous WCIRDC Coverage on CCKB](#)

## Useful Conference Links

- [Conference Website](#)
- [Conference Registration](#)
- [Conference Program](#)
- [Day-by-day Conference Preview](#)
- [Conference Scientific Committee](#)

## Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)
4. [Day #4 Highlights](#)

## Top Highlights

1. [Back to basics](#): Insulin resistance as a foundational defect in T2D pathogenesis
2. [“Pre-prediabetes”](#): The association between insulin resistance and cardiometabolic risk in people without obesity
3. [Beyond glycemic management](#): Visceral adiposity as a therapeutic target for HFpEF
4. [Cardiovascular prevention](#): Dr. Nathan Wong discusses the role of risk scores, coronary calcium and opportunistic testing for cardiometabolic disease
5. [Combination therapies for CKD and T2D](#): Dr. Jennifer Green spotlights clinical insights from the phase 2 CONFIDENCE trial
6. [Expanding real-world cardiometabolic care](#): Dr. Pam Taub on the potential of imaging
7. [Dr. Jorge Plutzky explains the role of angiogenesis](#) on cardiometabolic health
8. [Transforming diabetes care through AI-driven insulin models](#), decision support, and digital prevention
9. [Mechanistic impacts that may explain how body weight reduction](#) improves metabolic function in the eyes of Dr. Samuel Klein
10. [The role of the duodenum in metabolic dysfunction](#) by Dr. Richard Pratley

11. [Dr. Richard Pratley on Evoke trial results](#), muscle loss, and geriatric diabetes care
12. [Bayer's Kerendia \(finerenone\) improves morbidity and mortality in people with T2D](#) in people with either CKD or HF, irrespective of baseline A1c in a pooled analysis
13. [Liver and obesity](#): From shared pathogenesis to screening and management by Drs. Jennifer Green, Robert Kushner, and Amreen Dinani
14. [Dr. Brian Feldman explains moving beyond lifestyle interventions](#) to harness thermogenic fat in pediatric obesity
15. [Cortisol: The "forgotten hormone"](#) and the potential underlying factor that impacts insulin resistance
16. [In utero exposure to maternal hyperglycemia](#) and genetic risk independently increase T2D risk in adolescents, according to the HAPO study
17. [Dr. Yehuda Handelsman on hypertension](#) and lipid management
18. [Leptin and endotrophin as dual pillars of fibro-inflammation](#) in cardiometabolic disease
19. [Dr. Ralph DeFronzo on emerging therapies for beta cell regeneration](#) and insulin sensitization
20. [From the eyes of a cardiologist](#): Perspectives on healthy diets in cardiometabolic health for obesity management
21. [Pipeline updates from Zealand](#): Advancing amylin innovation and diversifying cardiometabolic therapies
22. [Pipeline updates from Novo Nordisk](#): Expanding incretin leadership and diversifying into inflammation and beyond
23. [Pipeline updates from AstraZeneca](#): Addressing root cause of cardiometabolic disease
24. [The role of the liver in the cardiovascular-kidney-metabolic syndrome](#)
25. [Peripheral artery disease in T2D](#): A modern epidemic of fragmented care
26. [CVOTs in 2025 for heart failure](#), lipid management, and hypertension
27. [Reframing hypercortisolism in T2D](#): Insights from the CATALYST trial from Dr. John Buse
28. [Gerald Reaven Award Lecture](#): Dr. Tracey McLaughlin details pathophysiology behind obesity and metabolic dysfunction
29. [Dr. Sunder Mudaliar explores the "incretin jungle"](#) from GIP paradox to emerging agents
30. [CGM in prediabetes](#): Sensor variability and the need for new standards
31. [Obesity burden and CGM benefits](#) in people with T1D
32. [Medical management of HFmrEF and HFpEF](#) with rapid sequence or simultaneous initiation of SGLT-2 inhibitors, nsMRAs, and GLP-1 RAs

## Previous WCIRDC Coverage on CCKB

- [WCIRDC 2024 Resource Hub](#)
- [WCIRDC 2023 Resource Hub](#)
- [WCIRDC 2022 Resource Hub](#)
- [WCIRDC 2021 Resource Hub](#)
- [WCIRDC 2020 Full Report](#)
- [WCIRDC 2018 Full Report](#)